HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Revance Therapeutics (NASDAQ:RVNC) but lowers the price target from $15 to $12.
February 23, 2024 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Revance Therapeutics' price target was lowered from $15 to $12 by HC Wainwright & Co., although the Buy rating was maintained.
The reduction in price target could suggest a more cautious outlook on the company's future performance. However, maintaining a Buy rating indicates the analyst still sees potential upside. This mixed signal could lead to neutral short-term price movement as investors digest both the positive and negative aspects of the analyst's outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100